Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Atopic Dermatitis/Atopic Eczema | Treatment Algorithms: Claims Data Analysis | Adult | US | 2019
MARKET OUTLOOK Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus, eczema, and, in some cases, disrupted sleep and poor quality of life. Topical agents (e.g.,…
Ulcerative Colitis | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2019
MARKET OUTLOOK Conventional therapies (5-ASAs, corticosteroids) are typically used to treat mild to moderate pediatric ulcerative colitis (UC), whereas tumor necrosis factor-alpha (TNF-α)…
Psoriatic Arthritis | Emerging Therapies | Xeljanz (tofacitinib) | US | Wave 3 | 2019
Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA) and the only other oral targeted therapy besides Celgene’s PDE-4 inhibitor, Otezla, approved for this indication…
Allergic Rhinitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Allergic Rhinitis (US)
Allergic rhinitis is a chronic immunoglobulin E-mediated respiratory response to environmental allergens. It is typically treated with intranasal corticosteroids, followed by antihistamines, mast…
Alzheimer’s Disease | Treatment Algorithms: Claims Data Analysis | Neuropsychiatric Therapies in Alzheimer’s Disease | US | 2019
Alongside putative disease-modifying therapies, the late-phase pipeline in Alzheimer’s disease (AD) features several therapies for the treatment of behavioral symptoms in AD. Symptoms such as…
Biosimilars | Emerging Biosimilars | Immunology | Adalimumab | Germany | Wave 1 | 2019
With the launch of four adalimumab biosimilars into the European market in October 2018—Amgevita (Amgen), Imraldi (Biogen), Hulio (Mylan), and Hyrimoz (Sandoz)—competition within the already…
Rheumatoid Arthritis | Emerging Therapies | Olumiant (baricitinib) | US | Wave 2 | 2019
Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis (RA) in the United States. Its launch comes years after that of Pfizer’s Jak inhibitor, Xeljanz (…
Noninfectious Uveitis of the Posterior Segment | Treatment Algorithms: Claims Data Analysis | US | 2019
Most uveitis-related vision loss is the result of chronic inflammation of the posterior segment of the eye (i.e., intermediate, posterior, and panuveitis). Although noninfectious anterior uveitis…
